What is it about?
Antiplatelet agents (APAs) are essential in the management of atheromatous disease. The number of patients on long-term antiplatelet therapy who require scheduled invasive procedures is increasing each year.
Featured Image
Photo by Marek Studzinski on Unsplash
Why is it important?
Managing antiplatelet therapy in the perioperative period remains a significant challenge for both cardiologists and anesthesiologists. Achieving a balance between the hemorrhagic risk associated with surgery and the thrombotic risk from modifying antiplatelet therapy is crucial.
Perspectives
Antiplatelet agents (APAs) are crucial in managing atheromatous disease, primarily to prevent arterial thrombosis and reduce the risk of recurrent acute atherothrombotic events. Surgery is a common reason for premature discontinuation of antiplatelet therapy, which significantly increases mortality and major adverse cardiac events, notably stent thrombosis [1].
Acquire Publications
Read the Original
This page is a summary of: Perioperative Management of Antiplatelet Agents by Anesthesiologists and Cardiologists, Journal of Anesthesia and Anesthetic Drugs, May 2025, Acquire Publications LLC,
DOI: 10.54289/jaad2500101.
You can read the full text:
Contributors
The following have contributed to this page
